KLK3 and metastatic neoplasm: The fact that the classical adaptive therapy protocol that we analyzed here performs very well under the vast majority of assumptions on the contribution of different cell types’ to the prostate specific antigen level is a very good news for both these other evolutionary therapies and patients with metastatic disease, as long as PSA remains the main marker for tumor progression.